Mattia Matasci

Otelfingen, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Exploring the 89 Zr/ 177 Lu Theranostic Pairing with an Extracellular Matrix Targeted Radiopharmaceutical Against Triple Negative Breast Cancer.

Exploring the 89 Zr/ 177 Lu Theranostic Pairing with an Extracellular Matrix Targeted Radiopharmaceutical Against Triple Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2025

Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix-Targeted Radiopharmaceutical against Triple-Negative Breast Cancer.

Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix-Targeted Radiopharmaceutical against Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2025

Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.

Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 24, 2024

A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells.

A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells.

Journal: HemaSphere
Published: March 26, 2024

Expression of Inflammatory Genes in Murine Lungs in a Model of Experimental Pulmonary Hypertension: Effects of an Antibody-Based Targeted Delivery of Interleukin-9.

Expression of Inflammatory Genes in Murine Lungs in a Model of Experimental Pulmonary Hypertension: Effects of an Antibody-Based Targeted Delivery of Interleukin-9.

Journal: Advances in respiratory medicine
Published: November 11, 2023

Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody.

Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody.

Journal: Cardiovascular research
Published: November 04, 2023

Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology.

Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology.

Journal: Global challenges (Hoboken, NJ)
Published: May 26, 2023

Targeted Interleukin-9 delivery in pulmonary hypertension: Comparison of immunocytokine formats and effector cell study.

Targeted Interleukin-9 delivery in pulmonary hypertension: Comparison of immunocytokine formats and effector cell study.

Journal: European journal of clinical investigation
Published: September 10, 2022

A DNA-encoded chemical library based on chiral 4-amino-proline enables stereospecific isozyme-selective protein recognition.

A DNA-encoded chemical library based on chiral 4-amino-proline enables stereospecific isozyme-selective protein recognition.

Journal: Nature chemistry
Published: September 02, 2022

Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody.

Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody.

Journal: Journal for immunotherapy of cancer
Published: August 30, 2022

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

Journal: Blood advances
Published: December 23, 2021

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.

Journal: International journal of molecular sciences
Published: August 18, 2021
Showing 1-12 of 32

Last Updated: 09/26/2026